Articles published by Terns Pharmaceuticals, Inc.

< Previous 1 2 Next >
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Leadership Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.